- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00969553
Dose Finding Study of BI 6727 (Volasertib) in Patients With Various Solid Cancers
A Phase I Single Dose Escalation Study of Two Dosing Schedules of BI 6727 Administered Intravenously in Asian Patients With Various Solid Cancers With Repeated Administration in Patients With Clinical Benefit
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Tainan, Taiwan
- 1230.16.886002 Boehringer Ingelheim Investigational Site
-
Taipei, Taiwan
- 1230.16.886001 Boehringer Ingelheim Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Patients with histologically or cytologically confirmed diagnosis of advanced solid cancer
- Age 18 years or older
- Written informed consent
- Eastern Cooperative Oncology Group (ECOG) performance score 2 or less
Exclusion criteria:
- Serious illness or concomitant non-oncological disease.
- Pregnancy or breast feeding
- Active infectious disease
- Absolute neutrophil count less than 1,500/cubic millimeter
- Platelet count less than 100,000/cubic millimeter
- Bilirubin greater than 1.5 mg/dL (> 26 µmol/L, SI unit equivalent)
- Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal
- Serum creatinine greater than 1.5x ULN.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: BI 6727
Schedule A
|
Dose level 1
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Dose Limiting Toxicities (DLT) in Cycle 1 for the Determination of the Maximum Tolerated Dose (MTD) of Volasertib
Time Frame: From first administration of study drug up to 3 weeks
|
Primary objective for this trial was to identify the MTD of volasertib for 2 dosing schedules.
The MTD was defined as the highest volasertib dose studied for which the incidence of DLT was less than 2/6 patients.
The MTD was defined on the basis of DLTs observed during the first treatment course only.
In this outcome measure the percentage of participants with DLTs in cycle 1 is presented.
|
From first administration of study drug up to 3 weeks
|
MTD of Volasertib
Time Frame: From the first administration of study drug up to 3 weeks
|
Primary objective for this trial was to identify the MTD of volasertib for 2 dosing schedules.
The MTD was defined as the highest volasertib dose studied for which the incidence of DLT was less than 2/6 patients.
This outcome measure shows the MTD.
|
From the first administration of study drug up to 3 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Incidence and Intensity of Drug-related AEs According to CTCAE v.3.0
Time Frame: From first administration of volasertib to 21 days after the last dose, up to 548 days
|
Percentage of participants with incidence and intensity of drug-related AEs according to Common Terminology Criteria for Adverse Events (CTCAE) v.3.0.
This endpoint will be presented as a percentage of patients with adverse event by treatment and the highest CTCAE grade of the related AE.
|
From first administration of volasertib to 21 days after the last dose, up to 548 days
|
Change From Baseline to Last Value on Treatment in Platelets
Time Frame: Baseline (Visit 1, prior to first administration of volasertib) and up to 21 days after last observation on treatment (up to 548 days)
|
This endpoint will be presented as a change from baseline to last value on treatment in platelets.
|
Baseline (Visit 1, prior to first administration of volasertib) and up to 21 days after last observation on treatment (up to 548 days)
|
Change From Baseline to Last Value on Treatment in Neutrophils
Time Frame: Baseline (Visit 1, prior to first administration of volasertib) and up to 21 days after last observation on treatment (up to 548 days)
|
This endpoint will be presented as a change from baseline to last value on treatment in neutrophils.
|
Baseline (Visit 1, prior to first administration of volasertib) and up to 21 days after last observation on treatment (up to 548 days)
|
Patient Performance
Time Frame: From first administration of volasertib to the last dose, up to 527 days
|
This endpoint will present the best clinical assessment.
The investigator will perform a clinical assessment.
An evaluation will be done whether the patient appears to be clinically improved, unchanged, or deteriorated.
The presented numbers show the percentage of patients.
|
From first administration of volasertib to the last dose, up to 527 days
|
Vital Signs (Blood Pressure)
Time Frame: Baseline (Visit 1, prior to the first administration of volasertib), up to 21 days after last observation on treatment (up to 548 days)
|
This endpoint will be presented as a change from baseline at last observation of systolic blood pressure (SBP), diastolic blood pressure (DBP) in millimeter of mercury (mmHg) and pulse rate (PR) in beats per minute (bpm).
In this outcome measure SBP and DBP are presented.
|
Baseline (Visit 1, prior to the first administration of volasertib), up to 21 days after last observation on treatment (up to 548 days)
|
Vital Signs (Pulse Rate)
Time Frame: Baseline (Visit 1, prior to the first administration of volasertib), up to 21 days after last observation on treatment (up to 548 days)
|
This endpoint will be presented as a change from baseline at last observation of systolic blood pressure (SBP), diastolic blood pressure (DBP) in millimeter of mercury (mmHg) and pulse rate (PR) in beats per minute (bpm).
In this outcome measure the pulse rate is presented.
|
Baseline (Visit 1, prior to the first administration of volasertib), up to 21 days after last observation on treatment (up to 548 days)
|
ECG
Time Frame: Baseline, 2 hours (before the end of infusion of volasertib) and 24 hours after first infusion in Cycle 1
|
This endpoint will be presented as a change from individual baseline in QT interval, corrected according to Fridericias formula (QTcF) to end of infusion (2 hours) and 24 hours after first infusion in Cycle 1.
|
Baseline, 2 hours (before the end of infusion of volasertib) and 24 hours after first infusion in Cycle 1
|
Objective Response
Time Frame: At screening and at the end of every other treatment course up to 527 days (= longest treatment exposure)
|
The objective response (OR) was defined as complete response (CR; disappearance of all target lesions) or partial response (PR; at least a 30 percent decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest) assessed by tumour measurement and evaluated according to the Response Evaluation Criteria in solid tumours (RECIST), version 1.0. The data represents the percentage of patients. |
At screening and at the end of every other treatment course up to 527 days (= longest treatment exposure)
|
Progression-free Survival
Time Frame: At screening and at the end of every other treatment course up to 527 days (= longest treatment exposure)
|
Progression-free survival (PFS) is defined as the duration of time from start of treatment to time of progression or death.
PFS was assessed by tumour measurement and evaluated according to RECIST, version 1.0.
|
At screening and at the end of every other treatment course up to 527 days (= longest treatment exposure)
|
Response Duration
Time Frame: From first drug administration up to at 3 month interval after final End of treatment visit until disease progression, death, or lost to follow-up, up to 548 days
|
The duration of overall response was measured from the time measurement criteria were met for complete response (CR) or partial response (PR), whichever was recorded first, until the first date that recurrent or progressive disease was objectively documented.
The duration of overall CR was measured from the time measurement criteria were first met for CR until the first date that recurrent disease was objectively documented.
|
From first drug administration up to at 3 month interval after final End of treatment visit until disease progression, death, or lost to follow-up, up to 548 days
|
Disease Control
Time Frame: At screening and at the end of every other treatment course up to 527 days (= longest treatment exposure)
|
The disease control (DC) presented are the percentage of patients with CR, PR or stable disease as best response throughout the study assessed by tumour measurement and evaluated according to RECIST, version 1.0.
|
At screening and at the end of every other treatment course up to 527 days (= longest treatment exposure)
|
Sum of the Largest Diameters of Target Lesions
Time Frame: At screening and at the end of every other treatment course up to 527 days (= longest treatment exposure)
|
The individual time profile of the sum of the largest diameters of target lesions (LD) is presented graphically for each patient in the Clinical Trial Report (CTR) only.
No descriptive statistics were planned.
|
At screening and at the end of every other treatment course up to 527 days (= longest treatment exposure)
|
Pharmacokinetics (PK) AUC0-∞ of Volasertib
Time Frame: Both schedules: 10 minutes prior to first drug administration and 1 hour (h), 2, 2:30, 3, 4, 8, 24, 336h thereafter; additional planned times in schedule D1+D8: 167:50, 169, 170, 170:30, 171, 172, 176, 192h; additional planned time in D1 schedule: 168h
|
The PK of volasertib will be presented for the area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) for the population attending the D1 schedule, the area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to 168 hours (AUC0-168) for the population attending the D1+ D8 schedule and the maximum measured concentration of volasertib in plasma (Cmax).
In this outcome measure AUC0-∞ is presented.
|
Both schedules: 10 minutes prior to first drug administration and 1 hour (h), 2, 2:30, 3, 4, 8, 24, 336h thereafter; additional planned times in schedule D1+D8: 167:50, 169, 170, 170:30, 171, 172, 176, 192h; additional planned time in D1 schedule: 168h
|
Pharmacokinetics (PK) AUC0-168 of Volasertib
Time Frame: Both schedules: 10 minutes prior to first drug administration and 1 hour (h), 2, 2:30, 3, 4, 8, 24, 336h thereafter; additional planned times in schedule D1+D8: 167:50, 169, 170, 170:30, 171, 172, 176, 192h; additional planned time in D1 schedule: 168h
|
The PK of volasertib will be presented for the area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) for the population attending the D1 schedule, the area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to 168 hours (AUC0-168) for the population attending the D1+ D8 schedule and the maximum measured concentration of volasertib in plasma (Cmax).
In this outcome measure AUC0-168 is presented.
|
Both schedules: 10 minutes prior to first drug administration and 1 hour (h), 2, 2:30, 3, 4, 8, 24, 336h thereafter; additional planned times in schedule D1+D8: 167:50, 169, 170, 170:30, 171, 172, 176, 192h; additional planned time in D1 schedule: 168h
|
Pharmacokinetics (PK) Cmax of Volasertib
Time Frame: Both schedules: 10 minutes prior to first drug administration and 1 hour (h), 2, 2:30, 3, 4, 8, 24, 336h thereafter; additional planned times in schedule D1+D8: 167:50, 169, 170, 170:30, 171, 172, 176, 192h; additional planned time in D1 schedule: 168h
|
The PK of volasertib will be presented for the area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) for the population attending the D1 schedule, the area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to 168 hours (AUC0-168) for the population attending the D1+ D8 schedule and the maximum measured concentration of volasertib in plasma (Cmax).
In this outcome measure Cmax is presented.
|
Both schedules: 10 minutes prior to first drug administration and 1 hour (h), 2, 2:30, 3, 4, 8, 24, 336h thereafter; additional planned times in schedule D1+D8: 167:50, 169, 170, 170:30, 171, 172, 176, 192h; additional planned time in D1 schedule: 168h
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 1230.16
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms
-
GlaxoSmithKlineCompleted
-
European Association for Endoscopic SurgeryWithdrawn
-
Amphia HospitalRecruitingColonic Neoplasms MalignantNetherlands
-
Moscow Clinical Scientific CenterRecruitingCecal Neoplasms | Colonic Neoplasms MalignantRussian Federation
-
Marquette General Health SystemUpper Michigan Brain Tumor CenterWithdrawnGlioma | MeningiomaUnited States
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedBrain Stem Neoplasms, Primary | Neoplasms, Brain StemUnited States
-
Chang Gung Memorial HospitalNational Science and Technology CouncilNot yet recruiting
-
GlaxoSmithKlineRecruitingNeoplasms, RectalUnited States, France, Italy, Japan, Spain, United Kingdom, Germany, Korea, Republic of, Canada, Netherlands
-
Russian Society of Colorectal SurgeonsRecruitingNeoplasms,ColorectalRussian Federation
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
Clinical Trials on BI 6727
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedNeoplasmsUnited States, Taiwan
-
Boehringer IngelheimCompleted
-
Northwestern UniversityNational Cancer Institute (NCI); National Comprehensive Cancer NetworkWithdrawnRecurrent Adult Acute Lymphoblastic Leukemia | Refractory Adult Acute Lymphoblastic LeukemiaUnited States
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedCarcinoma, Non-Small-Cell LungBahamas, Canada
-
University of AlbertaWithdrawnLeukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Acute | Leukemia, Monocytic, Acute | Leukemia, Megakaryoblastic, Acute | Leukemia, Erythroblastic, AcuteCanada
-
Boehringer IngelheimCompleted